Free Trial

eXoZymes (EXOZ) Competitors

eXoZymes logo
$9.98 +0.03 (+0.30%)
As of 07/25/2025 03:56 PM Eastern

EXOZ vs. ADCT, OLMA, BNTC, HRTX, ALDX, VOR, AVIR, CRDF, SGMT, and OCGN

Should you be buying eXoZymes stock or one of its competitors? The main competitors of eXoZymes include ADC Therapeutics (ADCT), Olema Pharmaceuticals (OLMA), Benitec Biopharma (BNTC), Heron Therapeutics (HRTX), Aldeyra Therapeutics (ALDX), Vor Biopharma (VOR), Atea Pharmaceuticals (AVIR), Cardiff Oncology (CRDF), Sagimet Biosciences (SGMT), and Ocugen (OCGN). These companies are all part of the "pharmaceutical products" industry.

eXoZymes vs. Its Competitors

ADC Therapeutics (NYSE:ADCT) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

eXoZymes has lower revenue, but higher earnings than ADC Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADC Therapeutics$75.82M4.30-$157.85M-$1.45-2.27
eXoZymes$70K1,193.32-$5.86MN/AN/A

eXoZymes has a net margin of 0.00% compared to ADC Therapeutics' net margin of -197.64%.

Company Net Margins Return on Equity Return on Assets
ADC Therapeutics-197.64% N/A -45.57%
eXoZymes N/A N/A N/A

41.1% of ADC Therapeutics shares are held by institutional investors. 5.4% of ADC Therapeutics shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ADC Therapeutics presently has a consensus target price of $7.75, suggesting a potential upside of 135.92%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe ADC Therapeutics is more favorable than eXoZymes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ADC Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
eXoZymes
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, eXoZymes had 1 more articles in the media than ADC Therapeutics. MarketBeat recorded 1 mentions for eXoZymes and 0 mentions for ADC Therapeutics. eXoZymes' average media sentiment score of 0.93 beat ADC Therapeutics' score of 0.00 indicating that eXoZymes is being referred to more favorably in the news media.

Company Overall Sentiment
ADC Therapeutics Neutral
eXoZymes Positive

Summary

eXoZymes beats ADC Therapeutics on 7 of the 12 factors compared between the two stocks.

Get eXoZymes News Delivered to You Automatically

Sign up to receive the latest news and ratings for EXOZ and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EXOZ vs. The Competition

MetriceXoZymesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$83.26M$3.07B$5.70B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E RatioN/A21.1828.1020.05
Price / Sales1,193.32286.17429.0189.19
Price / CashN/A42.7636.2258.56
Price / Book7.988.378.665.87
Net Income-$5.86M-$55.19M$3.25B$258.55M
7 Day Performance7.89%5.88%4.22%3.73%
1 Month Performance2.57%17.33%10.51%11.75%
1 Year PerformanceN/A4.42%34.40%18.03%

eXoZymes Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EXOZ
eXoZymes
N/A$9.98
+0.3%
N/AN/A$83.26M$70K0.0029Gap Up
ADCT
ADC Therapeutics
1.2406 of 5 stars
$3.12
+2.5%
$7.75
+148.8%
-14.0%$308.94M$75.82M-2.15310
OLMA
Olema Pharmaceuticals
2.4168 of 5 stars
$4.51
-1.1%
$24.50
+443.2%
-67.9%$308.58MN/A-2.2470Positive News
BNTC
Benitec Biopharma
1.7723 of 5 stars
$11.74
-0.1%
$23.83
+103.0%
+22.5%$308.18M$80K-7.7720High Trading Volume
HRTX
Heron Therapeutics
3.8111 of 5 stars
$2.00
-1.0%
$5.00
+150.0%
-38.4%$305.13M$148.52M-33.33300Positive News
ALDX
Aldeyra Therapeutics
2.5136 of 5 stars
$5.03
-2.5%
$9.50
+88.9%
+26.4%$301.28MN/A-5.1910Positive News
Upcoming Earnings
High Trading Volume
VOR
Vor Biopharma
3.8809 of 5 stars
$2.38
+12.3%
$5.63
+136.5%
+131.2%$297.41MN/A-1.44140High Trading Volume
AVIR
Atea Pharmaceuticals
2.619 of 5 stars
$3.46
-0.9%
$6.00
+73.4%
+0.0%$296.10MN/A-2.1070News Coverage
Positive News
CRDF
Cardiff Oncology
1.3795 of 5 stars
$4.45
+0.7%
$11.70
+162.9%
+67.9%$296.06M$680K-4.8420Positive News
SGMT
Sagimet Biosciences
2.6844 of 5 stars
$9.55
-0.1%
$26.60
+178.5%
+201.2%$292.90M$2M-5.438News Coverage
Analyst Forecast
Insider Trade
OCGN
Ocugen
1.2336 of 5 stars
$1.00
-3.8%
$6.00
+500.0%
-33.1%$292.03M$4.05M-5.2680Positive News

Related Companies and Tools


This page (NASDAQ:EXOZ) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners